Skip to main content

Table 3 Isolates with high IC50 to at least one anti-malarial drug among the 181 isolates tested

From: Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum

Isolates

IC50 in nM

origin

PND

PPQ

CQ

QN

MQ

MDAQ

LMF

DHA

AS

Mali

ND

175

22

185

23.4

44.8

25.8

1.2

2.0

Comoros

ND

177.5

130

460

27.6

76.4

15.8

1.2

3.2

Cameroon

15.0

189

171

217

8.0

16.3

7.0

2.0

1.9

Africa

28.4

217.3

1029

580

31.3

240.0

17.7

1.6

1.3

Côte d'Ivoire

31.2

172.8

60

377

68.0

4.6

58.0

5.3

4.0

Comoros

34.2

83.8

108

707

4.4

40.5

20.7

3.3

2.9

Gabon

37.2

90.2

1918

580

40.7

42.8

25.1

3.4

2.9

Comoros

36.1

214

145

292

15.8

69.3

8.1

1.1

1.4

Cameroon

40.2

181.6

444

576

3.2

171

5.4

0.8

0.6

Comoros

66.0

60.2

304

176

18.5

78.9

13.1

3.5

4.6

Niger

66.3

79.9

331

393

37.4

61.0

20.1

0.7

0.5

Comoros

66.7

82.6

244

918

3.5

46.6

14.1

0.8

0.8

Benin

67.4

82.4

17

728

5.3

21.7

36.4

3.0

2.2

Comoros

69.4

46.0

246

210

5.3

82.4

6.4

1.9

1.9

Thailand

71.5

91.1

63

1131

166

34.4

114.0

21.2

16.3

Côte d'Ivoire

76.1

91.0

288

660

7.8

56.0

1.4

1.3

1.8

Comoros

80.0

82.0

321

587

32.9

47.2

6.7

2.5

3.5

  1. High IC50s are in bold
  2. ND: not determined